arrow
N

Natalie Staplin

University of Oxford
H指数:42
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

在640万个人中预防和评分2心血管风险方程的跨国验证

2026-05-050
OAAI
Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study
2025-11-010
PRE
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY

恩格列净对EMPA-KIDNEY研究中尿液生物标志物的影响

2025-10-310
OAAI
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis

恩格列净对常规和探索性急性及慢性肾脏结局的影响:一项个体参与者水平的荟萃分析

2025-10-110
OAAI
Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis

慢性肾脏病与癌症发生风险:一项个体参与者数据荟萃分析

2025-09-060
OAAI
A Mendelian randomization study of the effect of body mass index on 52 causes of death among 125 000 Mexican adults with admixed ancestry
2025-08-010
OA
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

恩格列净对慢性肾病生活质量、医疗资源利用及成本的影响:EMPA-KIDNEY试验的健康经济学分析

2025-07-080
OA
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

醛固酮合成酶抑制剂vicadrostat(BI 690517)在慢性肾病中改善心肾结局的潜力:EASi-KIDNEY试验的依据

2024-11-122
OA